Belzutifan Patent Expiration
Belzutifan is Used for treating advanced renal cell carcinoma after previous treatment with specific inhibitors. It was first introduced by Merck Sharp And Dohme Corp A Sub Of Merck And Co Inc
Belzutifan Patents
Given below is the list of patents protecting Belzutifan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Welireg | US9908845 | Aryl ethers and uses thereof | Sep 05, 2034 | Merck Sharp Dohme |
| Welireg | US9969689 | Aryl ethers and uses thereof | Sep 05, 2034 | Merck Sharp Dohme |
| Welireg | USRE49948 | Aryl ethers and uses thereof | Sep 05, 2034 | Merck Sharp Dohme |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Belzutifan's patents.
Latest Legal Activities on Belzutifan's Patents
Given below is the list recent legal activities going on the following patents of Belzutifan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9969689 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9908845 |
| transaction for FDA Determination of Regulatory Review Period | 11 Dec, 2023 | US9969689 |
| transaction for FDA Determination of Regulatory Review Period | 11 Dec, 2023 | US9908845 |
| Second letter to regulating agency to determine regulatory review period | 30 May, 2023 | US9969689 |
| Second letter to regulating agency to determine regulatory review period | 30 May, 2023 | US9908845 |
| Letter from FDA or Dept of Agriculture re PTE application | 13 Sep, 2022 | US9969689 |
| Letter from FDA or Dept of Agriculture re PTE application | 13 Sep, 2022 | US9908845 |
| Patent Term Extension (156) Dismissed Critical | 12 Jan, 2022 | US9969689 |
| Patent Term Extension (156) Dismissed Critical | 12 Jan, 2022 | US9908845 |
Belzutifan's Family Patents
